

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|--|
| 1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these? |
|--|

No equality issues were identified during consultation.

- | |
|--|
| 2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|--|

Not applicable.

- | |
|---|
| 3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
|---|

Not applicable.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 19 02 13

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

During the draft scope consultation consultees noted that people from certain races are not accessing health care support as much as other racial groups and that people from rural locations may not have equal access to treatment. Both of these potential equality issues related to service configuration or implementation of health care and cannot be addressed in a Technology Appraisal.

It was also raised that overweight people are not included in dosing table in the SPC. This issue cannot be addressed by Appraisal Committee as it can only appraise a technology within the marketing authorisation.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No potential equality issues were raised in the submissions, expert statement or academic report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No potential equality issues have been identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
No issues relevant for the Committee's discussions were raised .

Approved by Associate Director (name): ...Dr. Elisabeth George.....

Date: 29/10/2012